|
|
 |
|
Viewing report
|
|
|
|
C. R. Bard Acquires Lutonix - Set to Gain from a New Technology - Deal Analysis from GlobalData
GlobalData, Jan 2012, Pages: 7
C. R. Bard Acquires Lutonix - Set to Gain from a New Technology - Deal Analysis from GlobalData
Summary
GlobalData’s report, “C. R. Bard Acquires Lutonix - Set to Gain from a New Technology” provides key information and analysis on the deal, C. R. Bard’s acquisition of the Lutonix. The report provides information on deal rationale that includes estimation analysis of the Peripheral Transluminal Coronary Angioplasty (PTCA) drug-eluting balloons market and key insights on the deal based on Bard’s strategies for inorganic growth.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Potential market opportunity in the Peripheral Transluminal Coronary Angioplasty (PTCA) drug-eluting balloons market.
- Qualitative analysis on Bard’s acquisition of Lutonix.
- C. R. Bard’s inorganic growth strategies in recent years.
Reasons to buy
- Develop business strategies by understanding the trends and developments that are driving the PTCA drug-eluting balloons market.
- Decide potential of investments in new market opportunities such as the PTCA drug-eluting balloons market.
- Design and develop your marketing and sales strategies
- Develop market expansion strategies.
- Exploit M&A opportunities by identifying key areas of growth
|
|
|
|
